Have a personal or library account? Click to login
Stereological Evaluation of the Brains in Patients with Parkinson’s disease Compared to Controls Cover

Stereological Evaluation of the Brains in Patients with Parkinson’s disease Compared to Controls

Open Access
|Aug 2017

References

  1. 1. Halliday GM, McCann H. The progression of pathology in Parkinson’s disease. Annals of the New York Academy of Sciences. 2010;1184(1):188-95. DOI: 10.1111/j.1749-6632.2009.05118.x10.1111/j.1749-6632.2009.05118.x
  2. 2. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889-909. DOI: 10.1016/S0896-6273(03)00568-310.1016/S0896-6273(03)00568-3
  3. 3. Santiago RM, Barbieiro J, Lima MM, Dombrowski PA, Andreatini R, Vital MA. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson’s disease are predominantly associated with serotonin and dopamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010;34(6):1104-14. DOI: 10.1016/j.pnpbp.2010.06.00410.1016/j.pnpbp.2010.06.004
  4. 4. Mounsey RB, Teismann P. Mitochondrial dysfunction in Parkinson’s disease: pathogenesis and neuroprotection. Parkinson’s Disease. 2010;2011.10.4061/2011/617472
  5. 5. Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N, et al. Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor fluctuations. Movement disorders. 2006;21(9):1384-95. DOI: 10.1002/mds.2099310.1002/mds.20993
  6. 6. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. The Lancet Neurology. 2006;5(6):525-35. DOI: 10.1016/S1474-4422(06)70471-910.1016/S1474-4422(06)70471-9
  7. 7. Lolaty HA, Tirgari A, Fard JH. Emotional intelligence and related factors in medical sciences students of an Iranian university. Iranian journal of nursing and midwifery research. 2014;19(2):203.
  8. 8. Fereshtehnejad S-M, Shafieesabet M, Rahmani A, Delbari A, Lökk J. Medium-to-high prevalence of screening- detected parkinsonism in the urban area of Tehran, Iran: data from a community-based door-to-door study. Neuropsychiatric disease and treatment. 2015;11:321. DOI: 10.2147/NDT.S7739110.2147/NDT.S77391
  9. 9. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. The Lancet Neurology. 2006;5(1):75-86. DOI: 10.1016/S1474-4422(05)70285-410.1016/S1474-4422(05)70285-4
  10. 10. Ciumas C, Montavont A, Ryvlin P. Magnetic resonance imaging in clinical trials. Current opinion in neurology. 2008;21(4):431-6. DOI: 10.1097/WCO.0b013e-3283056a3c
  11. 11. Halperin I, Morelli M, Korczyn AD, Youdim MB, Mandel SA. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases. Neurotherapeutics. 2009;6(1):128-40. DOI: 10.1016/j.nurt.2008.10.03310.1016/j.nurt.2008.10.033508426119110204
  12. 12. Casteleyn C, Prims S, Van Cruchten S, Van Ginneken C. Stereology: from astronomy to veterinary oncology. Veterinary journal (London, England: 1997). 2014;202(1):3-4. DOI: 10.1016/j.tvjl.2014.06.00110.1016/j.tvjl.2014.06.00124973003
  13. 13. Qualter P, Gardner KJ, Pope DJ, Hutchinson JM, Whiteley HE. Ability emotional intelligence, trait emotional intelligence, and academic success in British secondary schools: A 5year longitudinal study. Learning and Individual Differences. 2012;22(1):83-91. DOI: 10.1016/j.lindif.2011.11.00710.1016/j.lindif.2011.11.007
  14. 14. Brannick MT, Wahi MM, Goldin SB. Psychometrics of mayer-salovey-caruso emotional intelligence test (MSCEIT) scores 1. Psychological reports. 2011;109(1):327-37. DOI: 10.2466/03.04.PR0.109.4.327-33710.2466/03.04.PR0.109.4.327-33722049672
  15. 15. Duygulu S, Hicdurmaz D, Akyar I. Nursing students’ leadership and emotional intelligence in Turkey. Jour nal of Nursing Education. 2011;50(5):281-5. DOI: 10.3928/01484834-20110130-0710.3928/01484834-20110130-0721323258
  16. 16. Geng D-y, Li Y-X, Zee C-S. Magnetic resonance imaging- based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson’s disease. Neurosurgery. 2006;58(2):256-62. DOI: 10.1227/01.NEU.0000194845.19462.7B10.1227/01.NEU.0000194845.19462.7B16462479
  17. 17. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss W-D. Differentiating multiple system atrophy from Parkinson’s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. Journal of Neurology, Neurosurgery & Psychiatry. 2002;73(5):517-23. DOI: 10.1136/jnnp.73.5.51710.1136/jnnp.73.5.517173813112397143
  18. 18. Gocmen-Mas N, Pelin C, Canan S, Yazici AC, Zagyapan R, Senan S, et al. Stereological evaluation of volumetric asymmetry in healthy human cerebellum. Surgical and radiologic anatomy. 2009;31(3):177-81. DOI: 10.1007/s00276-008-0424-410.1007/s00276-008-0424-418941706
  19. 19. Heidari Z, Mahmoudzadeh-Sagheb H, Hashemi M, Rigi-Ladiz MA. Quantitative analysis of interdental Gingiva in patients with chronic periodontitis and transforming growth factor-β1 29C/T gene polymorphisms. Journal of periodontology. 2014;85(2):281-9. DOI: 10.1902/jop.2013.13008710.1902/jop.2013.13008723688102
  20. 20. Heidari Z, Mahmoudzadeh-Sagheb H, Kohan F. A quantitative and qualitative study of rat testis following administration of methadone and buprenorphine. International Journal of High Risk Behaviors and Addiction. 2012;1(1):14-7. DOI: 10.5812/ijhrba.411910.5812/ijhrba.4119
  21. 21. Lee CS, Schulzer M, de la Fuente-Fernández R, Mak E, Kuramoto L, Sossi V, et al. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Archives of neurology. 2004;61(12):1920-5. DOI: 10.1001/archneur.61.12.192010.1001/archneur.61.12.192015596613
  22. 22. Lewis MM, Smith AB, Styner M, Gu H, Poole R, Zhu H, et al. Asymmetrical lateral ventricular enlargement in Parkinson’s disease. European journal of neurology. 2009;16(4):475-81. DOI: 10.1111/j.1468-1331.2008.02430.x10.1111/j.1468-1331.2008.02430.x290827319187264
  23. 23. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magneticresonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. Journal of Neurology, Neurosurgery & Psychiatry. 2007;78(3):254-9. DOI: 10.1136/jnnp.2006.09384910.1136/jnnp.2006.093849211763317028119
  24. 24. Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch J, Evans A, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology. 2005;64(2):224-9. DOI: 10.1212/01.WNL.0000149510.41793.5010.1212/01.WNL.0000149510.41793.5015668417
  25. 25. Fahn S, Group PS. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? Journal of neurology. 2005;252(4):iv37-iv42. DOI: 10.1007/s00415-005-4008-510.1007/s00415-005-4008-516222436
  26. 26. Douaud G, Gaura V, Ribeiro M-J, Lethimonnier F, Maroy R, Verny C, et al. Distribution of grey matter atrophy in Huntington’s disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage. 2006;32(4):1562-75. DOI: 10.1016/j.neuroimage.2006.05.05710.1016/j.neuroimage.2006.05.05716875847
  27. 27. Mamah D, Wang L, Barch D, de Erausquin GA, Gado M, Csernansky JG. Structural analysis of the basal ganglia in schizophrenia. Schizophrenia research. 2007;89(1):59-71. DOI: 10.1016/j.schres.2006.08.03110.1016/j.schres.2006.08.031183981717071057
  28. 28. Summerfield C, Junqué C, Tolosa E, Salgado-Pineda P, Gómez-Ansón B, Martí MJ, et al. Structural brain changes in Parkinson disease with dementia: a voxel- based morphometry study. Archives of Neurology. 2005;62(2):281-5. DOI: 10.1001/archneur.62.2.28110.1001/archneur.62.2.28115710857
  29. 29. Cordato N, Duggins A, Halliday G, Morris J, Pantelis C. Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain. 2005;128(6):1259-66. DOI: 10.1093/brain/awh50810.1093/brain/awh50815843423
  30. 30. Menke RA, Szewczyk‐Krolikowski K, Jbabdi S, Jenkinson M, Talbot K, Mackay CE, et al. Comprehensive morphometry of subcortical grey matter structures in early‐stage Parkinson’s disease. Human brain mapping. 2014;35(4):1681-90. DOI: 10.1002/hbm.2228210.1002/hbm.22282686897023861334
  31. 31. Sterling NW, Du G, Lewis MM, Dimaio C, Kong L, Eslinger PJ, et al. Striatal shape in Parkinson’s disease. Neurobiology of aging. 2013;34(11):2510-6. DOI: 10.1016/j.neurobiolaging.2013.05.01710.1016/j.neurobiolaging.2013.05.017374268623820588
  32. 32. Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P, et al. MR imaging index for differentiation of progressive supranuclear palsy from parkinson disease and the parkinson variant of multiple system atrophy 1. Radiology. 2008;246(1):214-21. DOI: 10.1148/radiol.245306170310.1148/radiol.245306170317991785
  33. 33. Acharya HJ, Bouchard TP, Emery DJ, Camicioli RM. Axial signs and magnetic resonance imaging correlates in Parkinson’s disease. The Canadian Journal of Neurological Sciences. 2007;34(01):56-61. DOI: 10.1017/S031716710000579510.1017/S0317167100005795
  34. 34. Hu M, White S, Chaudhuri KR, Morris R, Bydder G, Brooks D. Correlating rates of cerebral atrophy in Parkinson’s disease with measures of cognitive decline. Journal of neural transmission. 2001;108(5):571-80. DOI: 10.1007/s00702017005710.1007/s00702017005711459077
  35. 35. Gama RL, Távora DF, Bomfim RC, Silva CE, Bruin VMd, Bruin PFd. Morphometry MRI in the differential diagnosis of parkinsonian syndromes. Arquivos de neuro- psiquiatria. 2010;68(3):333-8. DOI: 10.1590/S0004-282X201000030000110.1590/S0004-282X2010000300001
  36. 36. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Regional brain volumes distinguish PSP, MSA‐P, and PD: MRI‐based clinico‐radiological correlations. Movement disorders. 2006;21(7):989-96. DOI: 10.1002/mds.2087710.1002/mds.2087716602104
  37. 37. Ertekin T, Acer N, İçer S, Vurdem ÜE, Çınar Ş, Özçelik Ö. Volume estimation of the subcortical structures in Parkinson’s disease using magnetic resonance imaging: A methodological study. Neurology Asia. 2015;20(2):143-53.
  38. 38. Korbo L, Amrein I, Lipp HP, Wolfer D, Regeur L, Oster S, et al. No evidence for loss of hippocampal neurons in non‐Alzheimer dementia patients. Acta neurologica scandinavica. 2004;109(2):132-9. DOI: 10.1034/j.1600-0404.2003.00182.x10.1034/j.1600-0404.2003.00182.x14705976
  39. 39. Joelving F, Billeskov R, Christensen J, West M, Pakkenberg B. Hippocampal neuron and glial cell numbers in Parkinson’s disease-a stereological study. Hippocampus. 2006;16(10):826-33. DOI: 10.1002/hipo.2021210.1002/hipo.2021216941622
  40. 40. Jubault T, Brambati SM, Degroot C, Kullmann B, Strafella AP, Lafontaine A-L, et al. Regional brain stem atrophy in idiopathic Parkinson’s disease detected by anatomical MRI. PloS one. 2009;4(12):e8247. DOI: 10.1371/journal.pone.000824710.1371/journal.pone.0008247278429320011063
  41. 41. Toulouse A, Sullivan AM. Progress in Parkinson’s disease-where do we stand? Progress in neurobiology. 2008;85(4):376-92. DOI: 10.1016/j.pneurobio.2008.05.00310.1016/j.pneurobio.2008.05.00318582530
DOI: https://doi.org/10.1515/rrlm-2017-0010 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Language: English
Page range: 265 - 274
Submitted on: Jan 18, 2017
Accepted on: Feb 23, 2017
Published on: Aug 1, 2017
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2017 Zahra Heidari, Ali Moghtaderi, Hamidreza Mahmoudzadeh-Sagheb, Enam Alhagh Charkhat Gorgich, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.